articleTop 1% cited

A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis

British Journal of Dermatology · 2016 · Vol. 175(2) · pp. 273–286

Kim Papp✉(Probity Medical Research)Kristian Reich(Dermatologikum Hamburg)C. Paul(Université Toulouse III - Paul Sabatier)Andrew Blauvelt(Oregon Medical Research Center)Wojciech Baran(Wroclaw Medical University)Chantal Bolduc(Innovaderm (Canada))D. Toth(Probity Medical Research)Richard G. Langley(Dalhousie University)Jennifer Clay CatherAlice B. Gottlieb(Tufts Medical Center)Diamant Thaçi(University of Lübeck)James G. Krueger(Rockefeller University)Chris B. Russell(Amgen (United States))C.E. Milmont(Amgen (United States))Jing Li(Amgen (United States))Paul Klekotka(Amgen (United States))Greg Kricorian(Amgen (United States))Ajay Nirula(Amgen (United States))

View via DOI Publisher page

Abstract

Brodalumab therapy resulted in significant clinical benefit and an acceptable safety profile in patients with moderate-to-severe plaque psoriasis.

Psoriasis: Treatment and Pathogenesis Dermatology and Skin Diseases Vitamin D Research StudiesPlaque psoriasisMedicinePsoriasisDermatologyPlaceboDouble blindRandomized controlled trialPsoriasis Area and Severity IndexInternal medicinePathology

MeSH terms

Antibodies, MonoclonalAnxiety DisordersDepressive DisorderDermatologic AgentsDouble-Blind MethodDrug Administration ScheduleFemaleHumansMaleMiddle AgedPsoriasisBiomarkersTreatment OutcomeRetreatmentDrug Substitution